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Introduction
Vulvovaginal atrophy (VVA) is a prevalent condition af-
fecting many postmenopausal women.1 Up to 40% of post-
menopausal women develop symptoms of VVA.2-5 It is most 
often diagnosed by its symptoms, including vaginal dryness, 
burning, itching, vagina pain and dyspareunia. More re-
cently these symptoms have been described as a syndrome: 
the genitourinary syndrome of menopause (GSM).6,7 This 
new term describes various menopausal symptoms and signs 
including not only genital symptoms but sexual (pain) and 
urinary symptoms (dysuria, urgency) as well. The patho-
physiology of GSM/VVA can be explained by the decline in 
estrogen levels associated with diminished ovarian function 
and natural aging. 
Traditionally the treatment options for GSM/VVA was 
vaginal estrogen supplementation but many women are ei-
ther unable to or are afraid to use hormones. There are sev-
eral nonhormonal treatment modalities for the management 
of VVA related symptoms, especially for one of the most 
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bothersome symptoms of vaginal dryness. The 2013 posi-
tion statement of The North American Menopause Society 
indicates that the first-line therapies to alleviate symptoms 
of VVA should include nonhormonal vaginal lubricants and 
moisturizers as well as regular sexual activity.8 Although 
there are numerous vaginal moisturizers and lubricants are 
commercially available only a few of those have been tested 
in clinical trials. 
Previously we investigated the role of vaginal zinc 
supplementation on vaginal remodeling.9 We showed that in 
human vaginal smooth muscle cells, zinc has a beneficial 
effect on the production of extracellular components 
produced by the muscle at 20 μM zinc tissue level, thereby 
increasing the amount of elastin production.10 Earlier animal 
studies have shown that zinc plays an important role in 
the vaginal extracellular matrix (ECM) composition. When 
rats were kept on a zinc-lacking diet, the vaginal structure 
became similar to the menopausal vagina.11 With vaginal 
zinc replacement, the vaginal ECM could be regenerated 
with characteristics equivalent to juvenile rats.9
The primary aim of this pilot study was to test the 
effect of a novel zinc-containing vaginal gel on GSM/
VVA symptoms. Secondary objectives included identifying 
potential side effects and safety concerns with its use.
Materials and Methods
A prospective cohort study was performed with the 
enrollment of women with GSM at the outpatient clinic of 
the Department of Obstetrics and Gynecology, University 
of Debrecen, Hungary between March 2017 and March 
2018. Our study was approved by the Hungarian National 
Institutional Review Medical Research Council. Patients 
were enrolled after signed, informed consent was obtained 
(approval no. 7239-3/2017EIUG). Enrollment criteria included 
the presence of symptoms of vulvovaginal atrophy/GSM in 
postmenopausal women. To be defined as a postmenopausal 
woman, individuals had to have at least 12 consecutive 
months of amenorrhea without any other obvious reason/
or consistently elevated follicle-stimulating hormone blood 
levels of 30 mIU/mL or higher. Exclusion criteria were 
premenopausal state, local or systemic hormone therapy 
within the past six months, vaginal infection at presentation, 
cytological atypia, prior radiation treatment, history of 
breast, ovarian or other gynecological cancer, pelvic organ 
prolapse > stage 2, and the recent use (3 months) of any 
vaginal product or douching.
Patients were asked to use commercially available zinc 
containing vaginal gel (JUVIA vaginal gel; Fempharma 
Europe, LLC., Budapest, Hungary) daily for 2 weeks. 
The key ingredients of the gel are water, hydroxyethyl 
cellulose, zinc sulfate, and lactic acid. The novel gel was self-
applied intra vaginally via a vaginal applicator. Participants 
were asked to place 2 mL of gel into the vagina nightly 
for 2 consecutive weeks. Patients underwent a detailed 
gynecological exam at enrollment and 2 weeks after 
completing the treatment (about 4 weeks after enrollment). 
At the first visit general gynecological and medical history 
was taken (age, body mass index, previous deliveries or 
operations, menstruation cycle, the onset of menopause, 
and hormonal therapy). Demographic and pertinent clinical 
information was recorded prospectively and stored in a 
dedicated database.
Postmenopausal women with symptoms of GSM 
were asked to complete a questionnaire reporting their 
symptoms (vaginal pain, dyspareunia, vaginal dryness, 
burning, itching, and dysuria), and mark the severity of 
their symptoms on a 0–10 visual analogue scale (VAS). 
A score of 0 indicated the absence of a symptom and a 
score of 10 the worst possible symptoms. Also, a validated 
vulvovaginal symptom questionnaire (VSQ-21) was used 
to assess subjective symptoms before and 2 weeks after 
treatment.12 The clinical evaluation was performed by a 
board-certified obstetrician and gynecologist blinded to the 
specific study related information. The clinical data gathered 
included components of the Vaginal Health Index (VHI) 
score: elasticity, fluid secretion, pH and epithelial mucosa 
(integrity) and moisture components. Each component is 
scored on a scale of 1 (worst) to 5 (best).13 Lower scores 
indicate more severe atrophy. VHI was calculated at 
baseline and 2 weeks after the completion of treatment. 
In addition, a vaginal smear was obtained from the right 
lateral vaginal wall using a spatula and stained according 
to the Papanicolaou technique at baseline and 2 weeks 
after completion of the intervention. The cytology samples 
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were evaluated by an independent, blinded, board-certified 
pathologist trained and authorized to review vaginal 
cytology. The Vaginal Maturation Index (VMI) was evaluated 
by calculating the percentage of superficial, intermediate 
and parabasal epithelial cells on the smear. Subsequently, 
we calculated the vaginal maturation values (VMV) [(1 × 
%superficial) + (0.5 × %intermediate) + (0 × %parabasal)].1 
Study participants completed an online, anonymous, self-
administered questionnaire to give an opportunity to provide 
feedback after completion of the study. Those questions 
included: Q1-Have you experienced any side effects during 
or after completion of the treatment? (Answers: Yes or No). 
Q2-How satisfied were you with the moisturizing effect 
of the gel? (Answers: Likert-type scale 1–5). Q3-For how 
long did the moisturizing effect last after stopping the 
treatment? (Answer: days). Q4-How comfortable did you feel 
using the gel? (Answers: Likert-type scale 1–5). Q5-Did your 
vulvovaginal symptoms improve significantly? (Answers: Yes 
or No). Q6-Did you feel more self-confident after using the 
gel? (Answers: Yes or No). Q7-How satisfied were you with the 
gel? (Answers: Likert-type scale 1–5). Q8-Were you satisfied 
with the consistency of the gel? (Answers: Yes or No). Q9-
Were you satisfied with the smell of the gel? (Answers: Yes or 
No).
Statistical analysis was performed with SigmaStat/SPSS 
software (Systat Software Inc., San Jose, CA, USA). To de-
scribe the clinical and demographic characteristics, means ± 
standard deviation (SD) were used for continuous variables. 
Paired t test was used to compare differences before and 
after treatment results. Differences were considered signifi-
cant when P value was less than 0.05. Data are presented 
as mean values (± SD) if not otherwise specified.
Results
All patients were in menopause. The average age was 60 
± 9 years, and on average 11 ± 9 years had passed since 
their last menstrual period. The rest of the demographic 
information is as described in Table 1. The VHI improved 
significantly (13 ± 4 before vs. 17 ± 4 after completion of 
treatment, P < 0.01; Table 2). The largest incremental VHI 
component change occurred in vaginal moisture. In sixty 
percent of the women, the vaginal pH remained normalized 
(pH < 4.6) even 2 weeks after cessation of treatment.
The patient reported VAS combined score was significantly 
lower after the treatment (18 ± 14 before vs. 7 ± 12 after 
treatment, P < 0.01; Table 3). The largest improvement 
occurred in vaginal dryness, followed by dyspareunia, 
burning and itching. 
The VMI and VMV did not change significantly (Table 4). 
There were no signs of inflammation on vaginal cytology.
VSQ-21 combined scores also improved significantly (7.9 
± 5.5 before vs. 2.7 ± 3.6 after the intervention, P < 0.01). 
Again, scores significantly lower indicate symptom improve-
ment.
Table 1. Clinical and demographic characteristics of the study 
sample
Variable Data
Subjects 37 (100)
Age (y) 60 ± 9
Gravida 3 ± 2
Para 2 ± 1
Body mass index (kg/m2) 27 ± 4
Duration in menopause (y) 11 ± 9
Prior C-section 5 (13.5)
Prior hysterectomy/BSO 8 (21.6)
The data is presented as number (%) or mean ± standard devia-
tion. 
Gravida: number of pregnancies, Para: number of deliveries, C-
section: caesarean section, BSO: bilateral salpingo-oophorectomy.
Table 2. Vaginal Health Index before and after treatment with the 
vaginal gel
Variable Before treatment(n = 37)
After treatment
(n = 37) P value
Elasticity 2.8 ± 0.9 3.6 ± 1.0 < 0.01
Fluid secretion 2.5 ± 0.8 3.4 ± 1.0 < 0.01
Vaginal pH 2.6 ± 1.7 2.9 ± 1.7 0.47
Epithelial mucosa 2.8 ± 0.9 3.7 ± 1.0 < 0.01
Moisture 2.7 ± 1.0 3.5 ± 1.1 < 0.01
Total score 13.2 ± 4.3 17.1 ± 5.1 < 0.01
The data is presented as mean ± standard deviation. 
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Based on the anonymous online questionnaire, 97% re-
ported that during treatment their vagina was well moistur-
ized and 94% felt that the treatment was very comfortable. 
The moisturizing effect lasted for at least for 1 week after 
cessation of treatment in 75% of women. Eighty-two percent 
of participants felt more self-confident after using the gel 
and reported a significant improvement in the quality of the 
sexual relationship. Overall 92% of women were extremely 
satisfied or satisfied with the vaginal gel treatment. The 
consistency of the gel was satisfactory (not too thick or too 
liquid) to 85% of woman and every woman agreed that the 
smell of the gel was satisfactory. Side effects were rare and 
minor. Two women reported increased vaginal discharge. 
One of those women discontinued the treatment and her 
symptoms resolved after that. 
Discussion
Our prospective cohort pilot trial revealed that a novel 
zinc-containing vaginal moisturizer gel significantly improves 
postmenopausal vulvovaginal symptoms without serious 
side effects. The VHI, the patient reported VAS and VSQ-21 
scores improved significantly. The largest VAS improvement 
occurred in vaginal dryness, and not surprisingly the larg-
est incremental change occurred in vaginal moisture out of 
the VHI components. We did not see a change in the VMI 
or VMV consistent with the nonhormonal nature of the gel. 
There were no signs of inflammation on vaginal cytology 
and side effects were rare and minor.
Nonhormonal treatment options for VVA symptoms in-
clude lubricants (water, silicone or oil based) and moistur-
izers. Recently other treatment options for the alleviation 
of atrophy related symptoms were tried.14 Regular use of 
nonhormonal, long-acting vaginal moisturizing agents can 
significantly improve symptoms of vaginal dryness, decrease 
vaginal pH to premenopausal levels without affecting VMI 
but not as effectively as hormonal treatments.15-17 Although 
several lubricants and moisturizers are commercially avail-
able over the counter, very few clinical trials have been 
performed to show their safety and efficacy.15-18 In one study 
that did examine the safety of personal moisturizers and 
lubricants, investigators found that many water-based gels 
are hyperosmolar and may lead to epithelial cell damage and 
toxicity.18 The vaginal gel tested in our pilot trial has been 
rigorously evaluated and found to be nontoxic to epithelial 
cells and not hyperosmolar (unpublished data based on com-
munication with the manufacturer). Our clinical evaluation 
agrees with that. We have found no signs of inflammation 
on pelvic exam or evidence of increased inflammatory cells 
on cytology. In fact, we did not see any change in the cy-
tology at all (VMI, VMV, or evidence of inflammation). Two 
patients reported increased vaginal discharge, but none had 
evidence of infection or vaginal irritation on pelvic exam. No 
other gel related side effects were reported.
There are several potential mechanisms how the tested 
gel may have caused the improvement of the GSM-related 
Table 3. VAS score before and after treatment with the vaginal 
gel
Variable Before treatment(n = 37)
After treatment
(n = 37) P value
Vaginal pain 2.1 ± 3.3 1.3 ± 2.7 0.29
Burning sensation 3.1 ± 3.6 0.9 ± 2.3 < 0.01
Itching 2.4 ± 5.3 0.8 ± 2.4 0.02
Vaginal dryness 5.4 ± 3.7 2.0 ± 2.8 < 0.01
Dyspareunia 5.0 ± 4.2 2.0 ± 3.0 < 0.01
Dysuria 0.7 ± 1.7 0.31 ± 1.1 0.32
Total score 18.2 ± 14.8 7.0 ± 12.4 < 0.01
The data is presented as mean ± standard deviation.
VAS: visual analogue scale (0–10, lower scores indicates less both-
er). 
Table 4. Vaginal cytology with Maturation Index and maturation 
values before and after treatment with the vaginal gel 
Variable Before treatment(n = 37)
After treatment
(n = 37) P value
Maturation Index
  Parabasal (%) 26 ± 37 24 ± 33 0.86
  Intermediate (%) 64 ± 32 62 ± 30 0.78
  Superficial (%) 10 ± 13 14 ± 19 0.39
Maturation value 42 ± 22 45 ± 22 0.66
The data was presented as mean ± standard deviation.
None of the specimens showed signs of inflammation.
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symptoms. All of the key components of the gel could have 
contributed to the symptom improvement via different 
mechanisms. The formulation is based on water and 
hydroxyethyl cellulose polymer which can bind to the vaginal 
mucosa and keep the moisture on the epithelial surface. The 
lactic acid provides the appropriate acidic pH for maintaining 
the necessary vaginal environment favored by lactobacilli. 
The zinc sulfate heptahydrate complex binds 7 water 
molecules providing the necessary hydration to the atrophic 
vagina and zinc can also penetrate the vaginal mucosa and 
may reach the lamina propria and muscularis layer of the 
vagina.19
We have previously shown the beneficial effects of zinc 
on human cultured vaginal smooth muscles cells. Under 
culture conditions, we were able to significantly stimulate the 
vaginal smooth muscle cell elastin production within 48 hours 
after exposure to 20 μM of zinc sulfate.10 In addition, in a 
rat model, we were able to improve upon the quality of the 
vaginal wall by vaginal zinc supplementation for 2 weeks in 
oophorectomized rats.9 The vaginal wall (epithelium, lamina 
propria, and muscularis) was significantly thicker, the ratio 
of vaginal collagen I/III and I/V expressions was significantly 
up-regulated compared to placebo after the application of zinc-
containing vaginal suppositories.9
There are several limitations to our pilot study. First and 
most importantly we are limited by the small number of 
women enrolled. In addition, the short-term nature of the 
study precludes our ability to assess the long-term effects 
of the gel. The design of the study (single cohort without a 
comparison group) does not allow us to conclude whether a 
specific ingredient or if the placebo effect is responsible for 
the improved clinical signs and patient-reported subjective 
symptoms. Only a large-scale, randomized, placebo-controlled 
trial could definitively answer those questions. Lastly, even 
though the online, anonymous self-reported questionnaire 
gave an opportunity for our study participants to report on 
their experiences with the vaginal gel, this questionnaire 
has not been validated.
In summary, the novel zinc-containing vaginal 
moisturizing gel has significantly improved the GSM/VVA 
symptoms of postmenopausal women. With this pilot study, 
we have created the foundation for a larger comparative 
study. We plan to conduct a larger scale, randomized, 
placebo-controlled trial in the near future to assess the 
benefits of a zinc-containing vaginal gel compared with both 
a placebo group and an estrogen-containing vaginal gel 
group.
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